In acquired hemophilia A (AHA), autoantibodies to coagulation factor VIII (FVIII) neutralize
FVIII activity leading to a potentially severe bleeding diathesis that carries a high rate of …

Autoantibodies against plasma coagulation factors could be developed by some individuals
inducing severe and sometimes fatal bleedings. This clinical entity is called acquired …

Background Acquired haemophilia A (AHA) is a rare bleeding disorder due to
autoantibodies to coagulation factor VIII that may be secondary to autoimmune diseases …

Acquired hemophilia A (AHA) is a rare severe autoimmune bleeding disorder with significant
morbidity and mortality. Although critical for disease control, there is no consensus for the …

Acquired hemophilia A (AHA) is an inhibitory coagulopathy that represents a rare variant of
hemorrhagic syndromes. We present a case of idiopathic AHA in a 75-year-old male patient …

Disorders of coagulation, resulting in serious risks for bleeding, may be caused by
autoantibody formation or by mutations in genes encoding coagulation factors. In the latter …

3. DISCUSSION AHA is a rare disorder caused by autoantibodies against endogenous FVIII
that result in bleeding and affect between 1.2 and 1.5 persons per million per year. 5 Risk …

Introduction Acquired haemophilia A (AHA) is a rare bleeding disorder, characterised by the
presence of autoantibodies to clotting factor VIII (FVIII). AHA can be idiopathic or occur in the …

Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder. Various autoimmune
diseases, including AHA, have been reported to occur after the administration of mRNA …

Acquired haemophilia A (AHA) is a rare bleeding disorder with high morbidity and mortality,
but it is eminently treatable if diagnosis and treatment are prompt. We report a case of AHA …